1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Korean Drug Co., Ltd

Korean Drug Co., Ltd

KKRX:014570
2,950.00
KRW
-80.00
(-2.64%)
638.80EPS
6.19P/E
42.81BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,809.46
4,177.58
4,328.17
5,070.76
5,075
4,764.76
5,089.2
6,143.82
6,818.78
7,416.69
7,547.02
6,775.85
5,778.59
5,800.38
Basic EPS, GAAP
65
198
162
463
429
601
357
677
828
1,095
-456
278
602
638.8
Free Cash Flow per Basic Share
340.99
344.39
479.92
321.08
-63.45
405.42
288.39
1,064.36
700.21
-52.33
-244.57
355.14
1,168.03
981.31
Dividend per Share
70.59
60.45
69.99
70.13
99.96
89.95
99.93
100.22
149.65
169.99
180.03
150.18
159.96
179.99
Book Value per Share
4,332.09
4,460.48
4,546.42
4,917.69
5,220.49
5,759.32
5,970.82
6,507
7,111.75
7,855.42
7,146.81
7,222.25
7,674.66
7,603.88
Tangible Book Value per Share
4,306.23
4,392.3
4,464.79
4,844.77
5,144.05
5,690.81
5,911.15
6,445.23
7,087.35
7,809.93
7,113.17
7,202.93
7,655.37
7,584.41
Basic Weighted Avg Shares
11
11
11
11
11
11
11
11
11
11
11
11
11
11
Sales/Revenue/Turnover
41,555
45,392
47,391
55,308
55,403
52,028
55,529
66,789
74,466
79,984
81,375
73,001
62,509
62,760
Operating Margin (%)
2.49
6.25
5.35
11.09
9.56
6.78
6.15
16.53
15.13
17.91
22.15
12.52
11.06
11.61
Depreciation Expense
955
966
965
922
954
1,033
1,184
1,355
1,470
1,383
1,749
2,069
1,969
1,966
Net Income, GAAP
709
2,151
1,774
5,050
4,683
6,562
3,895
7,360
9,042
11,809
-4,917
2,995
6,512
6,912
Effective Tax Rate (%)
9.99
2.15
32
16.76
13.78
19.27
12.47
20.35
20.12
19.58
159.49
40.02
16.49
17.14
Profit Margin (%)
1.71
4.74
3.74
9.13
8.45
12.61
7.01
11.02
12.14
14.76
-6.04
4.1
10.42
11.01
Working Capital
33,682
34,640
33,130
36,888
40,128
44,373
44,150
53,184
60,121
65,205
53,524
55,715
60,774
61,178
LT Debt
3,000
2,000
500
500
- -
- -
26
6
15
22
16
18
15
27
Total Equity
47,423
48,791
49,679
53,662
56,973
62,799
65,050
70,871
76,690
84,713
77,090
78,106
83,072
82,306
Return on Invested Capital (%)
1.67
5.12
3.29
9.61
8.24
4.83
4.76
12.98
12.06
14.07
-12.96
6.94
7.1
7.56
Return on Capital (%)
1.82
4.32
3.44
9.49
8.36
10.89
6.1
10.82
12.25
14.62
-6.07
3.86
8.08
8.66
Return on Common Equity (%)
1.49
4.47
3.6
9.77
8.47
10.96
6.09
10.83
12.26
14.63
-6.08
3.86
8.08
8.67

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
57
43
56
LT Borrowings
- -
- -
- -
LT Finance Leases
21
15
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
47,823
46,544
42,810

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
70,677
69,066
72,050
Cash, Cash Equivalents & STI
29,032
29,996
34,540
Accounts Receivable, Net
23,064
23,142
20,598
Inventories
18,102
15,526
16,483
Total Current Liabilities
9,750
8,292
10,872
Payables & Accruals
- -
- -
- -
ST Debt
57
43
56
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.43%
3.47%
6.36%
Free Cash Flow
-44.23%
42.22%
230.22%
Net Income, GAAP
13.42%
-26.34%
117.42%
Sales/Revenue/Turnover
3.38%
-0.8%
-14.37%
Total Cash Common Dividend
10.18%
11.67%
6.94%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,313
18,967
17,017
17,704
73,001
2025
13,086
14,937
16,486
18,000
62,509
2026
13,338
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
311
-103
250
-178.74
278
2025
75
183.92
176.39
167.51
602
2026
111
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
150.24
- -
- -
- -
150.18
2025
161.89
- -
- -
- -
159.96
2026
179.93
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
Full Time Employees
238
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Icheon-si South Korea
IPO Date
Dec 7, 2000
Website
nicepharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Korean Drug Co., Ltd. is a South Korea-based pharmaceutical and healthcare manufacturing company engaged in the research, development, production, and marketing of herbal medicines, ethical pharmaceuticals, over-the-counter medications, and health functional foods. Founded in 1961 and headquartered in Nonsan, Chungcheongnam-do, South Korea, with corporate and sales offices in Seoul, the company operates across specialized pharmaceutical segments supplying domestic medical institutions, pharmacies, and international healthcare distributors. The company's core product portfolio encompasses traditional and standardized herbal extract formulations, including Phellinus linteus mushroom-derived immune-enhancing formulations and anticancer adjuvant therapeutics; botanical granule extracts, decoctions, and liquid formulas for respiratory, digestive, and circulatory health; ethical pharmaceuticals (ETC), comprising cardiovascular agents, gastrointestinal treatments, metabolic regulators, antibiotics, and anti-inflammatory and analgesic medications prescribed by hospitals and clinics; over-the-counter (OTC) drugs, such as cold and cough remedies, herbal tonics, antipyretics, digestive aids, and dermatological ointments; and health functional foods, featuring mushroom mycelium extracts, red ginseng formulations, vitamins, and specialized dietary supplements designed to support metabolic health and immune function. In addition to finished dosage formulations, the company produces active pharmaceutical ingredients (APIs) and standardized botanical raw materials. In recent developments, Korean Drug Co., Ltd. has advanced its strategic growth initiatives through investments in manufacturing automation and quality assurance enhancements at its KGMP-compliant production facilities, expanding its contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) service capacities. The company has broadened its commercial footprint by entering into strategic distribution alliances with regional healthcare providers and wholesale pharmacy networks across South Korea, while actively expanding the international export of its flagship botanical extract products to select markets throughout Asia and overseas territories. Furthermore, the company continues to advance clinical research and R&D pipelines focused on standardized natural compound therapeutics, expanding its high-value health functional food lineup and modernizing traditional botanical delivery mechanisms to address increasing clinical demand for integrative and natural pharmaceutical solutions.